Mallinckrodt (MNK) wins IPR decisions on INOMax blood-vessel drug - Bloomberg

September 16, 2016 9:56 AM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Mallinckrodt (NYSE: MNK) wins IPR decisions on INOMax blood-vessel drug, according to Bloomberg.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Litigation, Trader Talk

Add Your Comment